Insider Transactions in Q4 2020 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2020
|
Christopher D Alafi Director |
BUY
Grant, award, or other acquisition
|
Direct |
495
+0.14%
|
$15,345
$31.8 P/Share
|
|
Dec 31
2020
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
495
+0.8%
|
$15,345
$31.8 P/Share
|
|
Dec 31
2020
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
222
+2.68%
|
$6,882
$31.8 P/Share
|
|
Dec 31
2020
|
Richard A Lerner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
471
+0.49%
|
$14,601
$31.8 P/Share
|
|
Dec 18
2020
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+2.88%
|
$68,000
$2.74 P/Share
|
|
Dec 17
2020
|
Joel S Marcus |
BUY
Bona fide gift
|
Indirect |
28,379
+29.59%
|
-
|
|
Dec 17
2020
|
Joel S Marcus |
SELL
Bona fide gift
|
Direct |
28,379
-100.0%
|
-
|
|
Nov 17
2020
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
79,425
-97.63%
|
$2,144,475
$27.78 P/Share
|
|
Nov 17
2020
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+48.57%
|
$975,000
$13.86 P/Share
|
|
Nov 11
2020
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
28,034
-100.0%
|
$700,850
$25.41 P/Share
|
|
Nov 11
2020
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.98%
|
$60,000
$3.05 P/Share
|
|
Nov 10
2020
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-2.17%
|
$1,300,000
$26.45 P/Share
|
|
Nov 04
2020
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-4.12%
|
$1,250,000
$25.0 P/Share
|
|
Oct 16
2020
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,792
-19.45%
|
$176,592
$26.8 P/Share
|
|
Oct 15
2020
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,448
+27.81%
|
-
|